Letters
Lenacapavir in HIV prevention
Gilead’s anti-diversion clause for lenacapavir exploits vulnerable communities
BMJ 2024; 387 doi: https://doi.org/10.1136/bmj.q2659 (Published 29 November 2024) Cite this as: BMJ 2024;387:q2659
- Alejandra Armenta Espinosa, HIV advocate1,
- Timothy P Daly, postdoctoral researcher in public health2
- 1College of Ethnologists and Social Anthropologists, Mexico City, Mexico
- 2UMR 1219 Bordeaux Population Health, University of Bordeaux and INSERM, Bordeaux, France
- timothy.daly{at}u-bordeaux.fr
Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV prevention in vulnerable populations, Gilead’s anti-diversion clause to make the generic formula unavailable in certain middle income countries where trial participants live is more than what Yamey and Machingaidze call “a missed …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.